TECVAYLI™ is a bispecific antibody that uses innovative science to target BCMA and engage T-cells to activate the immune system1
BCMA, B-cell maturation antigen; CD3, cluster of differentiation 3; MM, multiple myeloma.
- TECVAYLI™ (teclistamab-cqyv) Prescribing Information. Janssen Biotech, Inc., Horsham, PA 19044.
- US Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Accessed March 7, 2023. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma
Explore the efficacy of TECVAYLI™
Register to stay up-to-date with important information about TECVAYLI™Sign Up
Connect with a Janssen Oncology representativeTalk With Us
Access resources to help patients receive TECVAYLI™Explore Resources